Navigation Links
Nutrastar Announces Record 2010 Performance and Revenue Guidance for 2011

HARBIN, China, March 28, 2011 /PRNewswire-Asia-FirstCall/ --

Financial Highlights for the Year Ended December 31, 2010:

  • Revenues increased 58.1% to $24.2 million
  • Gross profit increased 82% to $19.6 million, a gross margin of 80.9%
  • Net income rose 73.6% to $13.4 million, representing a net margin of 55.5%
  • Basic earnings per share ("EPS") increased to $0.80; Diluted EPS increased to $0.79

  • Nutrastar International Inc. (OTC Bulletin Board: NUIN; "Nutrastar" or the "Company"), a leading producer and supplier of premium branded Traditional Chinese Medicine ("TCM") consumer products, today announced record financial results for the year ended December 31, 2010 and revenue guidance for the year ending December 31, 2011. For year 2010, revenues and net income both posted an increase of over 50% from year 2009.

    Ms. Lianyun Han, CEO of Nutrastar, commented, "Despite global economic challenges and inflationary pressures, Nutrastar continues to sell at full production capacity and post improved financial results quarter after quarter. Our performance in 2010 has resulted in double digit growth on both the top and bottom line. We hope to see a continuation of this upward trend looking into the remainder of 2011 and in years to come."

    Total revenue generated from sales of Nutrastar's consumer products was $24.24 million, an increase of $8.91 million or 58.1% from approximately $15.33 million for the same period in 2009. The increase was primarily as a result of an increase in demand for the Company's core product, commercially cultivated Cordyceps Militaris ("Chinese Golden Grass"), combined with an increase in the average selling price of approximately 20%.

    The Company's revenue is categorized into three segments based on our consumer product portfolio. In 2010, revenue from our commercially cultivated Cordyceps Militaris was $22.04 million, revenue from our organic and specialty food products was approximately $1.78 million and revenue from our newly introduced functional health beverage product line was approximately $0.43 million. The functional health beverage product line was introduced and rolled out initially in select cities in the province of Jiangsu in mid-November 2010.

    Overall gross profit was $19.6 million, an increase of $8.84 million or 82% from approximately $10.77 million during the same period in 2009. Gross margin was 80.9% for the year ended December 31, 2010, an increase of 15.2% from 70.2% in 2009. Cost of goods sold, comprised of costs related to raw materials, labor and overhead, was $4.64 million for 2010, an increase of $0.08 million, or 1.6% from approximately $4.56 million in 2009. As a percentage of revenues, the cost of goods sold decreased to 19.1% in 2010 from 29.8% in 2009. This improved performance was a result of continued product mix shift towards smaller packages of Cordyceps with higher gross margins combined with decreased cost of goods due to improved production processes and economies of scale.

    Income before income taxes was approximately $15.66 million, up $6.69 million or 74.5% from $8.98 million in the same period of 2009. As a percentage of revenues, income before income taxes increased to 64.6% in 2010 from 58.6% in 2009.

    Net income was $13.44 million, an increase of $5.7 million or 73.7% from $7.74 million in the full year 2009.

    Basic and diluted EPS for the year ended December 31, 2010 was $0.80 and $0.79, based on 14.33 million and 14.48 million shares outstanding, respectively, an increase of $0.21 per basic and diluted share from the same period in 2009 when there were approximately 13.13 million basic and 13.34 million diluted shares outstanding.

    Financial Position as of December 31, 2010

    At December 31, 2010, the Company had cash and cash equivalents totaling $40.76 million, total assets of approximately $55.0 million, working capital of $39.37 million and stockholders' equity of $52.0 million. The Company generated $15.35 million in net cash from operating activities for the year ended December 31, 2010.

    Commenting on the annual results, Ms. Han stated, "2010 was a year of great strides and accomplishments for our Company. Having successfully completed a significant portion of our capacity expansion plan, we've now brought our annual capacity to 72 tons going into 2011. Capacity expansion will continue through 2011 and 2012 and upon completion of the current plan, we expect capacity to reach over 100 tons going into year 2013. Nutrastar saw the highest recorded sales of our core Cordyceps products, hitting $22.04 million for the year. Cordyceps products, especially our high-margin, small packaged products, have continued to see strong sales growth and steady order flow. Earnings per share have continued to rise significantly, resulting in increased value to our shareholders."

    Ms. Han continued, "In the fourth quarter of 2010, we launched our new Cordyceps based functional health beverage product line into the affluent Jiangsu province and in January 2011, we opened our first specialty store in Daqing City. Nutrastar's "Ban Ke Chong Cao" functional health drink is a reasonably priced "on-the-go" option for many Chinese consumers. These drinks are currently sold in over 80 supermarkets, convenience stores, hotels and restaurants. Our mass commercialization plans for the year include further expansion into Jiangsu as well as other select regions in China where market studies suggest that demand for our products is strong and widespread. Just last week, we announced the introduction of our entry-level 310 ml "Yang Yang Ba," which will be available through some of our current distribution channels and our specialty store beginning in April 2011. Through our distribution channels, we've posted initial sales for our new functional health beverages in the amount of $0.43 million for 2010. We expect considerable growth in this part of our business moving forward.

    On the new product front, we are currently working on our initial rollout of our commercially cultivated Cordyceps-based alcohol products. We completed the trial production in the first quarter of this year and anticipate getting the Cordyceps-based alcohol to market by the second half of 2011 through our specialty store and other distribution channels."

    "We believe that through our popular core product, commercially cultivated Cordyceps, coupled with our new beverage line, we'll continue to grow our market share in the consumer products space and further our position as a leading nutraceutical consumer products player in China. We are pleased that the Company turned a strong performance in 2010 and look forward to what 2011 will bring. We appreciate the support of our shareholders and will continue to keep the investment community apprised of our accomplishments in the China consumer marketplace," concluded Ms. Han.

    Guidance for the Year Ending December 31, 2011

    For the year ending December 31, 2011, based on management's current expectations, revenue will be in the range of $32.0 million to $36.0 million.  The company intends to utilize its existing cash position for capacity expansion, marketing and distribution of its new beverage products and general corporate purposes.

    Recent Events

    For more information regarding Nutrastar's financial performance during the year ended December 31, 2010, please refer to the Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on March 29, 2011.

    Conference Call

    Nutrastar will host a conference call at 8:30 a.m. EDT on Tuesday, March 29, 2011, to discuss the Company's fiscal year 2010 financial results. Ms. Lianyun Han, Chief Executive Officer, and Mr. Robert Tick, Chief Financial Officer, will be hosting the call.

    To participate in the live conference call, please dial the following number five to ten minutes prior to the scheduled conference call time: +1 (877) 407-0784 for U.S. based callers or +1 (201) 689-8560 for international callers. The conference call pass code is 369253.

    If you are unable to participate in the live call, a replay will be available for 14 days starting on Tuesday, March 29, 2011 at 11:30 a.m. ET. To access the replay, U.S. based callers should dial +1 (877) 870-5176, international callers should dial +1 (858) 384-5517. The conference pass code will remain 369253.NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME(AMOUNTS EXPRESSED IN US DOLLARS)Year Ended December 31,20102009NET REVENUE$24,241,688$15,332,445Cost of goods sold(4,637,951)(4,563,965)GROSS PROFIT19,603,73710,768,480Selling expenses(1,092,598)(507,587)General and administrative expenses(2,722,939)(1,356,499)Income from operations15,788,2008,904,394Other income (expenses):   Interest income124,03681,542   Foreign exchange differences(130,779)(15,398)   Loss on disposal of fixed assets(102,675)-   Change in fair value of warrants(15,413)-   Others, net-6,388   Total other income (expenses)(124,831)72,532Income before income taxes 15,663,3698,976,926Provision for income taxes(2,219,190)(1,235,210)NET INCOME 13,444,1797,741,716OTHER COMPREHENSIVE INCOME:Foreign currency translation adjustments1,286,69824,150COMPREHENSIVE INCOME$14,730,877$7,765,866Earnings per share   Basic




    0.59   Diluted




    0.58Weighted average number of shares outstanding   Basic14,327,79913,131,521   Diluted14,476,34913,341,521NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(AMOUNTS EXPRESSED IN US DOLLARS)December 31,20102009ASSETSCURRENT ASSETS   Cash and cash equivalents




    20,115,677   Restricted cash193,075-   Accounts receivable261,223215,486   Inventories867,761616,073   Prepayments and other receivables289,502251,235Total current assets42,370,40921,198,471OTHER ASSETS   Intangible assets, net 2,379,4352,747,402   Property, plant and equipment, net10,248,98910,396,507Total assets$54,998,833$34,342,380LIABILITIES AND STOCKHOLDERS' EQUITYCURRENT LIABILITIES   Accounts payable




    863   Other payables and accruals746,643453,504   Payable for intangible asset-878,709   Taxes payable696,519319,873   Due to related parties51,33949,794   Preferred stock dividend payable181,181-   Warrants liabilities1,198,273-   Acquisition payable-8,736,833Total current liabilities2,999,79810,439,576Total liabilities2,999,79810,439,576COMMITMENTS AND CONTINGENCIESSTOCKHOLDERS' EQUITY   Preferred Stock, $0.001 par value, (1,000,000 shares authorized,
    97,706 shares and none shares issued and outstanding,
    respectively; aggregate liquidation preference amount: $5,535,768
    and $nil, plus accrued but unpaid dividend of $181,181 and $nil, at
    December 31, 2010 and 2009, respectively4,508,914-   Common stock, $0.001 par value, 190,000,000 shares authorized,
    4,332,731 and 14,297,731 shares issued and outstanding at
    December 31, 2010 and 2009, respectively14,33314,298   Additional paid-in capital15,541,2074,715,891   Statutory reserves1,348,0711,341,687   Retained earnings28,326,89616,858,012   Accumulated other comprehensive income2,259,614972,916Total stockholders' equity51,999,03523,902,804Total liabilities and stockholders' equity $54,998,833$34,342,380NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(AMOUNTS EXPRESSED IN US DOLLARS)Year Ended December 31,20102009CASH FLOWS FROM OPERATING ACTIVITIES:   Net income




    7,741,716   Adjustments to reconcile net income to cash provided by operating
      activities:Change in fair value of warrants15,413-IR warrant expense52,170-Depreciation and amortization1,019,1881,004,386Share-based compensation expense219,89125,000Loss from disposal of fixed assets 102,675-   (Increase) decrease in assets:Accounts receivable (38,204)68,574Inventories(227,528)552,874Prepayments and other receivables1,406(237,020)Increase (decrease) in liabilities:Accounts payable122,243(2,345)Other payables and accruals275,183(19,890)Taxes payable358,768200,193Due to related parties-(8,998)Net cash provided by operating activities15,345,3849,324,490CASH FLOWS FROM INVESTING ACTIVITIES:   Purchase of property, plant and equipment(421,638)(49,155)   Proceeds from disposal of fixed assets203,086-Net cash used in investing activities(218,552)(49,155)CASH FLOWS FROM FINANCING ACTIVITIES:   Net proceeds from Private Placement 5,483,9192,500,000   Increase in restricted cash (193,075)-   Advances from related parties -49,773   Repayment of acquisition payable-(50,269)   Repayment of payables for intangible asset(886,328)(878,349)Net cash provided by financing activities4,404,5161,621,155  Foreign currency translation adjustment1,111,82320,944INCREASE IN CASH AND CASH EQUIVALENTS20,643,17110,917,434CASH AND CASH EQUIVALENTS, at the beginning of the year20,115,6779,198,243CASH AND CASH EQUIVALENTS, at the end of the year$ 40,758,848$20,115,677NON-CASH TRANSACTIONS   Share-based payment to employees under equity incentive plan




    25,000   Share-based payment – IR warrants




    -Release of VIE acquisition payable








    907,835About Nutrastar International Inc.Nutrastar is a China based leading producer and supplier of premium branded TCM consumer products including commercially cultivated Cordyceps Militaris and functional health beverages. Cordyceps Militaris is one of the most highly regarded herbal nutrients in TCM. The Company believes it is the largest manufacturer of bioengineered Chinese Golden Grass in China, ranked by volume, according to China Market Monitoring Center (CMMC), accounting for approximately 19% market share in China. The Company is headquartered in Harbin, capital of Heilongjiang province, with a total of 321 employees of which 21 are engaged in R&D, and 140 in sales and marketing. The products of Nutrastar are sold throughout China via a direct and distribution network that covers more than 10 provinces. More information may be found at or e-mail:

    Make sure you are first to receive timely up-to-date information on Nutrastar. Sign up for Nutrastar's email news alert system today at:

    Safe Harbor StatementThis news release contains "forward-looking statements" relating to the business of Nutrastar International Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements" including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, the Company does not assume a duty to update any forward-looking statements to reflect events or circumstances after the date hereof.

    For more information, please contact:Robert Tick, CFONutrastar International Inc.Email: Howard GostfrandAmerican Capital VenturesTel:  +1-305-918-7000Email:

    SOURCE Nutrastar International Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Nutrastar to Present at the Cowen and Company 9th Annual Consumer Conference in NYC
    2. Optimer Pharmaceuticals Announces Presentation at Upcoming SHEA Annual Meeting Regarding Hospital CDI Patients at Risk of Recurrence and Mortality
    3. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
    4. Med Ad News Magazine Announces Nominees for the 22nd Annual Manny Awards as Well as Advertising Person of the Year
    5. ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2010 and to Provide a Business Update
    6. Dynasplint Systems Announces New Product
    7. Pioneer Surgical Technology Announces Full Market Release of the Streamline TL Spinal Fixation System
    8. MASEP Infini Announces U.S. FDA 510(k) Clearance of State-of-the-art, Non-invasive Stereotactic Neurosurgery Technology
    9. ICAP Ocean Tomo Announces Auction of Patch Based Drug Delivery and Monitoring Techniques from Entrega Laboratories, LLC
    10. Huifeng Bio-Pharmaceutical Technology Announces New Senior Vice President of Finance
    11. Pervasis Therapeutics Announces Late-Breaking Oral Presentation at American Association for Cancer Research Annual Meeting
    Post Your Comments:
    (Date:10/12/2017)... 2017   Divoti USA will engrave and ... standard of the latest FDA requirements, which stipulates new criteria regarding ... in need of Medical ID jewelry such as Medical ID Bracelets, ... engraved in terms of the new FDA requirements . ... Divoti offers this dark mark fiber ...
    (Date:10/11/2017)... Texas , Oct. 11, 2017  True ... services, has amplified its effort during National Breast ... about hereditary cancer risks. ... of Clinical Oncology calculated that more than 10 ... have inherited mutations in BRCA1 or BRCA2 and have ...
    (Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), ... will showcase a range of technology and learning solutions at the 68th Annual ... Expo to be held October 14–18, 2017 at the Mandalay Bay Resort in ...
    (Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
    (Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
    (Date:10/12/2017)... ... 2017 , ... HMP , a leader in healthcare events and education, today ... Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & ... award competition recognizes editorial and design excellence across a range of sectors. This year’s ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
    Breaking Medicine News(10 mins):